Antibody engineering & therapeutics virtual 2020
14 December 2020
Abzena will be attending the virtual Antibody engineering & therapeutics event from 14th-16th December 2020. If you would like to join us you can register for the event here. Antibody engineering & therapeutics is the number 1 antibody engineering conference for accelerating next generation antibodies to commercial success. We will also be presenting at the […] Read more
WEBINAR- Oligonucleotide ADC design and development – an emerging field building on the success of ADCs in cancer
18 February 2021
Register for our webinar here. Antibody-drug conjugates (ADCs) are an established class of biopharmaceuticals with therapeutic applications in oncology and beyond. Antibody-oligonucleotide conjugates (AOCs) are a growing sub-class of ADCs that utilize the oligonucleotide functionality in combination with the antibody’s exquisite targeting ability and improved biodistribution profile. This approach significantly broadens the therapeutic potential of […] Read more